share_log

石藥集團：截至2024年9月30日止九個月之季度業績

CSPC PHARMA: QUARTERLY RESULTS FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2024

HKEX ·  Nov 15 12:01

Summary by Futu AI

石藥集團公佈截至2024年9月30日止九個月未經審核綜合業績，顯示收入總額為人民幣226.86億元，較去年同期下跌4.9%。其中，成藥業務收入下跌3.5%，原料產品下跌5.2%，功能食品及其他下跌21.9%。股東應佔基本溢利下跌15.2%至人民幣39.99億元，股東應佔溢利下跌15.9%至人民幣37.78億元。研發費用較去年同期增加5.5%至人民幣38.80億元，約佔成藥業務收入的20.8%。本期內，石藥集團在中國及北美市場均有新藥獲批上市，並在全球範圍內進行多項臨床試驗。此外，公司於2024年9月與江蘇康寧傑瑞訂立獨家授權許可協議，並於10月與阿斯利康訂立獨家授權協議，涉及一系列藥品的全球開發、製造及商業化。公司認為，非香港財務報告準則指標更能反映集團之基本經營業績。
石藥集團公佈截至2024年9月30日止九個月未經審核綜合業績，顯示收入總額為人民幣226.86億元，較去年同期下跌4.9%。其中，成藥業務收入下跌3.5%，原料產品下跌5.2%，功能食品及其他下跌21.9%。股東應佔基本溢利下跌15.2%至人民幣39.99億元，股東應佔溢利下跌15.9%至人民幣37.78億元。研發費用較去年同期增加5.5%至人民幣38.80億元，約佔成藥業務收入的20.8%。本期內，石藥集團在中國及北美市場均有新藥獲批上市，並在全球範圍內進行多項臨床試驗。此外，公司於2024年9月與江蘇康寧傑瑞訂立獨家授權許可協議，並於10月與阿斯利康訂立獨家授權協議，涉及一系列藥品的全球開發、製造及商業化。公司認為，非香港財務報告準則指標更能反映集團之基本經營業績。
CSPC Pharma announced its unaudited comprehensive performance for the nine months ended September 30, 2024, showing a total revenue of RMB 22.686 billion, a 4.9% decrease from the same period last year. Among them, revenue from pharmaceutical business decreased by 3.5%, raw material products by 5.2%, and functional foods and others by 21.9%. Shareholder's share of basic profit decreased by 15.2% to RMB 3.999 billion, and shareholder's share of profit decreased by 15.9% to RMB 3.778 billion. Research and development expenses increased by 5.5% to RMB 3.88 billion compared to the same period last year, accounting for approximately 20.8% of pharmaceutical business revenue. During this period, CSPC Pharma obtained approvals for new drugs in both China and North American markets and conducted multiple clinical trials globally. Additionally, the company entered into an exclusive licensing agreement with Jiangsu KonRun Jerui in September 2024 and with AstraZeneca in October for the global development, manufacturing, and commercialization of a range of pharmaceutical products. The company believes that non-Hong Kong Financial Reporting Standards indicators can better reflect the group's fundamental operational performance.
CSPC Pharma announced its unaudited comprehensive performance for the nine months ended September 30, 2024, showing a total revenue of RMB 22.686 billion, a 4.9% decrease from the same period last year. Among them, revenue from pharmaceutical business decreased by 3.5%, raw material products by 5.2%, and functional foods and others by 21.9%. Shareholder's share of basic profit decreased by 15.2% to RMB 3.999 billion, and shareholder's share of profit decreased by 15.9% to RMB 3.778 billion. Research and development expenses increased by 5.5% to RMB 3.88 billion compared to the same period last year, accounting for approximately 20.8% of pharmaceutical business revenue. During this period, CSPC Pharma obtained approvals for new drugs in both China and North American markets and conducted multiple clinical trials globally. Additionally, the company entered into an exclusive licensing agreement with Jiangsu KonRun Jerui in September 2024 and with AstraZeneca in October for the global development, manufacturing, and commercialization of a range of pharmaceutical products. The company believes that non-Hong Kong Financial Reporting Standards indicators can better reflect the group's fundamental operational performance.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated